Arvinas doses first patient in Phase 1/2 trial of ARV-6723 in solid tumors

The study will generate initial safety, drug-behavior and early antitumor readouts. ARV-6723 is being tested alone and with pembrolizumab in patients previously treated with checkpoint inhibitors.